loading
Travere Therapeutics Inc stock is traded at $18.36, with a volume of 284.26K. It is up +2.55% in the last 24 hours and up +1.19% over the past month. Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
See More
Previous Close:
$17.86
Open:
$17.96
24h Volume:
284.26K
Relative Volume:
0.16
Market Cap:
$1.55B
Revenue:
$203.45M
Net Income/Loss:
$-351.45M
P/E Ratio:
-4.0608
EPS:
-4.52
Net Cash Flow:
$-369.41M
1W Performance:
-0.84%
1M Performance:
+1.19%
6M Performance:
+177.09%
1Y Performance:
+224.17%
1-Day Range:
Value
$17.89
$18.41
1-Week Range:
Value
$16.86
$18.55
52-Week Range:
Value
$5.12
$20.33

Travere Therapeutics Inc Stock (TVTX) Company Profile

Name
Name
Travere Therapeutics Inc
Name
Phone
888-969-7879
Name
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Name
Employee
380
Name
Twitter
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
TVTX's Discussions on Twitter

Compare TVTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
TVTX 18.34 1.55B 203.45M -351.45M -369.41M -4.52
VRTX 448.10 115.74B 10.63B -479.80M -1.35B 13.33
REGN 742.32 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 589.59 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.38 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.70 24.49B 3.30B -501.07M 1.03B 11.54

Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-27-24 Downgrade Guggenheim Buy → Neutral
Dec-05-23 Upgrade Citigroup Neutral → Buy
Nov-20-23 Initiated Citigroup Neutral
Sep-22-23 Downgrade Wells Fargo Overweight → Equal Weight
Sep-21-23 Downgrade William Blair Outperform → Mkt Perform
Sep-06-23 Resumed Evercore ISI Outperform
Jul-21-23 Initiated JP Morgan Overweight
Jun-07-23 Resumed Piper Sandler Neutral
May-22-23 Initiated TD Cowen Outperform
May-05-23 Upgrade Bryan Garnier Sell → Neutral
Mar-01-23 Initiated Guggenheim Buy
Feb-21-23 Upgrade Wedbush Neutral → Outperform
Dec-14-22 Initiated Stifel Hold
Dec-05-22 Initiated Wells Fargo Overweight
Sep-21-22 Initiated Bryan Garnier Sell
Jul-14-22 Resumed Canaccord Genuity Buy
Mar-31-22 Initiated Piper Sandler Overweight
Feb-28-22 Initiated H.C. Wainwright Buy
May-26-21 Downgrade Wedbush Outperform → Neutral
View All

Travere Therapeutics Inc Stock (TVTX) Latest News

pulisher
03:38 AM

Oppenheimer & Co. Inc. Acquires New Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

03:38 AM
pulisher
Nov 19, 2024

Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level - Yahoo! Voices

Nov 19, 2024
pulisher
Nov 18, 2024

Travere: Q3 Earnings Snapshot - AOL

Nov 18, 2024
pulisher
Nov 18, 2024

Los Angeles Capital Management LLC Has $391,000 Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

Nov 18, 2024
pulisher
Nov 15, 2024

When (TVTX) Moves Investors should Listen - Stock Traders Daily

Nov 15, 2024
pulisher
Nov 15, 2024

Exploring Three High Growth Tech Stocks in the United States - Simply Wall St

Nov 15, 2024
pulisher
Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires Significant Stake in Travere The - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Woodline Partners LP Expands Stake in Travere Therapeutics Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Deep Track Capital, LP Reduces Stake in Travere Therapeutics Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $22.00 - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 13, 2024
pulisher
Nov 13, 2024

Travere Therapeutics Awards 24,400 RSUs to New Employees in Talent Acquisition Push | TVTX Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Alport Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook Therapeutics - The Globe and Mail

Nov 13, 2024
pulisher
Nov 13, 2024

Travere Therapeutics Completes $143.8 Million Public Offering - Marketscreener.com

Nov 13, 2024
pulisher
Nov 12, 2024

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares - The Manila Times

Nov 12, 2024
pulisher
Nov 11, 2024

3 Under-the-Radar Healthcare Companies - sharewise

Nov 11, 2024
pulisher
Nov 11, 2024

3 Under-the-Radar Healthcare Companies to Watch - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Unitedhealth Group Inc (UNH-N) QuotePress Release - The Globe and Mail

Nov 11, 2024
pulisher
Nov 10, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Nov 10, 2024
pulisher
Nov 09, 2024

Travere Therapeutics (NASDAQ:TVTX) Reaches New 12-Month HighHere's What Happened - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

TVTX stock soars to 52-week high, hits $19.29 amid robust gains - Investing.com India

Nov 08, 2024
pulisher
Nov 08, 2024

Latham & Watkins Advises on Travere Therapeutics’ Public Offering of Common Stock - Latham & Watkins LLP

Nov 08, 2024
pulisher
Nov 08, 2024

Travere Therapeutics plans public stock offering By Investing.com - Investing.com Australia

Nov 08, 2024
pulisher
Nov 07, 2024

Travere Therapeutics Announces Pricing of Public Offering of Common Stock - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Travere Therapeutics Announces Pricing of Public Offering of Common Stock - Benzinga

Nov 07, 2024
pulisher
Nov 07, 2024

Travere Therapeutics plans public stock offering - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

Travere Therapeutics Launches Public Stock Offering, Led by Jefferies & Leerink | TVTX Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 05, 2024

Travere Therapeutics' SWOT analysis: filspari approval boosts rare disease stock outlook - Investing.com UK

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Travere Therapeuti - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 04, 2024
pulisher
Nov 04, 2024

Travere Therapeutics to Present at Upcoming Investor Conferences - The Manila Times

Nov 04, 2024
pulisher
Nov 03, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Holdings Raised by Emerald Mutual Fund Advisers Trust - MarketBeat

Nov 03, 2024
pulisher
Nov 03, 2024

Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Scotiabank Analyst Says - Defense World

Nov 03, 2024
pulisher
Nov 01, 2024

TVTXTravere Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 01, 2024
pulisher
Nov 01, 2024

Scotiabank Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Evercore ISI raises Travere Therapeutics target to $33 By Investing.com - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid Operational Challenges - GuruFocus.com

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics Boosts Sales with FILSPARI Approval - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry - Simply Wall St

Oct 31, 2024
pulisher
Oct 31, 2024

Travere Therapeutics earnings beat by $1.34, revenue topped estimates - Investing.com Australia

Oct 31, 2024
pulisher
Oct 31, 2024

Travere Therapeutics Inc Reports Q3 2024 Revenue of $62.9 Millio - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Travere Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times

Oct 31, 2024

Travere Therapeutics Inc Stock (TVTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):